160 related articles for article (PubMed ID: 20232090)
21. Markers to predict the efficacy of bevacizumab in the treatment of metastatic colorectal cancer.
Varol U; Yildiz I; Salman T; Karabulut B; Uslu R
Tumori; 2014; 100(4):370-6. PubMed ID: 25296585
[TBL] [Abstract][Full Text] [Related]
22. Targeted vaccination against the bevacizumab binding site on VEGF using 3D-structured peptides elicits efficient antitumor activity.
Wentink MQ; Hackeng TM; Tabruyn SP; Puijk WC; Schwamborn K; Altschuh D; Meloen RH; Schuurman T; Griffioen AW; Timmerman P
Proc Natl Acad Sci U S A; 2016 Nov; 113(44):12532-12537. PubMed ID: 27791128
[TBL] [Abstract][Full Text] [Related]
23. Positron emission tomography imaging and biodistribution of vascular endothelial growth factor with 64Cu-labeled bevacizumab in colorectal cancer xenografts.
Paudyal B; Paudyal P; Oriuchi N; Hanaoka H; Tominaga H; Endo K
Cancer Sci; 2011 Jan; 102(1):117-21. PubMed ID: 21070475
[TBL] [Abstract][Full Text] [Related]
24. 89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922.
Nagengast WB; de Korte MA; Oude Munnink TH; Timmer-Bosscha H; den Dunnen WF; Hollema H; de Jong JR; Jensen MR; Quadt C; Garcia-Echeverria C; van Dongen GA; Lub-de Hooge MN; Schröder CP; de Vries EG
J Nucl Med; 2010 May; 51(5):761-7. PubMed ID: 20395337
[TBL] [Abstract][Full Text] [Related]
25. Optimization of Early Response Monitoring and Prediction of Cancer Antiangiogenesis Therapy via Noninvasive PET Molecular Imaging Strategies of Multifactorial Bioparameters.
Bao X; Wang MW; Luo JM; Wang SY; Zhang YP; Zhang YJ
Theranostics; 2016; 6(12):2084-2098. PubMed ID: 27698942
[No Abstract] [Full Text] [Related]
26. Monitoring early tumor response to drug therapy with diffuse optical tomography.
Flexman ML; Vlachos F; Kim HK; Sirsi SR; Huang J; Hernandez SL; Johung TB; Gander JW; Reichstein AR; Lampl BS; Wang A; Borden MA; Yamashiro DJ; Kandel JJ; Hielscher AH
J Biomed Opt; 2012 Jan; 17(1):016014. PubMed ID: 22352664
[TBL] [Abstract][Full Text] [Related]
27. Bevacizumab-induced normalization of blood vessels in tumors hampers antibody uptake.
Arjaans M; Oude Munnink TH; Oosting SF; Terwisscha van Scheltinga AG; Gietema JA; Garbacik ET; Timmer-Bosscha H; Lub-de Hooge MN; Schröder CP; de Vries EG
Cancer Res; 2013 Jun; 73(11):3347-55. PubMed ID: 23580572
[TBL] [Abstract][Full Text] [Related]
28. (99)mTc-(CO)(3) His-annexin A5 micro-SPECT demonstrates increased cell death by irinotecan during the vascular normalization window caused by bevacizumab.
Vangestel C; Van de Wiele C; Van Damme N; Staelens S; Pauwels P; Reutelingsperger CP; Peeters M
J Nucl Med; 2011 Nov; 52(11):1786-94. PubMed ID: 22045708
[TBL] [Abstract][Full Text] [Related]
29. Phage display-derived peptides for osteosarcoma imaging.
Sun X; Niu G; Yan Y; Yang M; Chen K; Ma Y; Chan N; Shen B; Chen X
Clin Cancer Res; 2010 Aug; 16(16):4268-77. PubMed ID: 20570932
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of VEGF induces cellular senescence in colorectal cancer cells.
Hasan MR; Ho SH; Owen DA; Tai IT
Int J Cancer; 2011 Nov; 129(9):2115-23. PubMed ID: 21618508
[TBL] [Abstract][Full Text] [Related]
31. A novel peptide specifically targeting the vasculature of orthotopic colorectal cancer for imaging detection and drug delivery.
Li ZJ; Wu WK; Ng SS; Yu L; Li HT; Wong CC; Wu YC; Zhang L; Ren SX; Sun XG; Chan KM; Cho CH
J Control Release; 2010 Dec; 148(3):292-302. PubMed ID: 20854857
[TBL] [Abstract][Full Text] [Related]
32. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic.
Ranieri G; Patruno R; Ruggieri E; Montemurro S; Valerio P; Ribatti D
Curr Med Chem; 2006; 13(16):1845-57. PubMed ID: 16842197
[TBL] [Abstract][Full Text] [Related]
33. Integration of novel agents in the treatment of colorectal cancer.
Iqbal S; Lenz HJ
Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
[TBL] [Abstract][Full Text] [Related]
34. Bevacizumab in colorectal cancer: current and future directions.
Yeung Y; Tebbutt NC
Expert Rev Anticancer Ther; 2012 Oct; 12(10):1263-73. PubMed ID: 23113577
[TBL] [Abstract][Full Text] [Related]
35. VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer.
Terme M; Pernot S; Marcheteau E; Sandoval F; Benhamouda N; Colussi O; Dubreuil O; Carpentier AF; Tartour E; Taieb J
Cancer Res; 2013 Jan; 73(2):539-49. PubMed ID: 23108136
[TBL] [Abstract][Full Text] [Related]
36. [Anti-angiogenic treatments in metastatic colorectal cancer: Does a continuous angiogenic blockade make sense?].
Jary M; Borg C; Bouché O; Kim S; André T; Bennouna J
Bull Cancer; 2015 Sep; 102(9):758-71. PubMed ID: 26232849
[TBL] [Abstract][Full Text] [Related]
37. Interleukin-8 as a modulator of response to bevacizumab in preclinical models of head and neck squamous cell carcinoma.
Gyanchandani R; Sano D; Ortega Alves MV; Klein JD; Knapick BA; Oh S; Myers JN; Kim S
Oral Oncol; 2013 Aug; 49(8):761-70. PubMed ID: 23623402
[TBL] [Abstract][Full Text] [Related]
38. Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma.
Patterson DM; Gao D; Trahan DN; Johnson BA; Ludwig A; Barbieri E; Chen Z; Diaz-Miron J; Vassilev L; Shohet JM; Kim ES
Angiogenesis; 2011 Sep; 14(3):255-66. PubMed ID: 21484514
[TBL] [Abstract][Full Text] [Related]
39. Vascular biology support for the use of bevacizumab in colorectal cancer.
Doggrell SA
Expert Opin Investig Drugs; 2004 Jun; 13(6):703-5. PubMed ID: 15174956
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of hypericin-mediated photodynamic therapy in combination with angiogenesis inhibitor bevacizumab using in vivo fluorescence confocal endomicroscopy.
Bhuvaneswari R; Thong PS; Gan YY; Soo KC; Olivo M
J Biomed Opt; 2010; 15(1):011114. PubMed ID: 20210440
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
